CAR T-cell therapy

Cecilia BrownChronic Lymphocytic Leukemia | October 24, 2022
Next-line CAR-T or venetoclax-based therapy led to longer OS than other approved next-line treatments.
Read More
Cecilia BrownMeeting News | October 6, 2022
Autologous chimeric antigen receptor (CAR) T-cell therapies have shown “unprecedented efficacy” in patients with ...
Leah SherwoodTransplantation & Cellular Therapy | October 6, 2022
Carlos de Lima, MD, stopped by the Blood Cancers Today booth at the 2022 SOHO Annual Meeting to give his advice...
Leah SherwoodMyeloma | September 30, 2022
Blood Cancers Today Editor-in-Chief Sagar Lonial, MD, FACP, provides an update...
Cecilia BrownChronic Lymphocytic Leukemia | September 30, 2022
As treatments for CLL evolve, new challenges have arisen to address the disease’s resistance to targeted therapies.
Kerri FitzgeraldPrint | September 13, 2022
In his President's Letter, Moshe Talpaz, MD, discusses all of the treatment progress made for hematologic malignancies.
Leah LawrenceTransplantation & Cellular Therapy | September 13, 2022
Blood Cancers Today spoke with clinicians about the two available second-line chimeric antigen receptor T-cell therapies...
Leah SherwoodMyeloma | September 12, 2022
CART-ddBCMA demonstrated a 100% overall response rate in patients with relapsed/refractory multiple myeloma.
Cecilia BrownMyeloma | August 30, 2022
Doris Hansen, MD, of the Moffitt Cancer Center, spoke about the research during an oral abstract presentation at IMS.
Leah SherwoodMyeloma | August 30, 2022
A single infusion of ciltacabtagene autoleucel “resulted in deep and durable responses” in...
Leah SherwoodAcute Lymphoblastic Leukemia | August 10, 2022
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use has issued...
Leah SherwoodTransplantation & Cellular Therapy | August 10, 2022
The largest study yet comparing chimeric antigen receptor (CAR) T-cell therapy with the previous standard of care (SOC)...
Leah SherwoodPrint | August 9, 2022
In second-line therapy for relapsed/refractory LBCL, which patients would you consider eligible for CAR T-cell therapy...
Leah SherwoodTransplantation & Cellular Therapy | August 6, 2022
The CAR T-cell therapy received accelerated approval for adults with R/R FL after two or more lines of systemic therapy.
Leah SherwoodChronic Lymphocytic Leukemia | August 5, 2022
This article discusses managing the most difficult cases of CLL.
Leah SherwoodAggressive B-Cell Lymphoma | August 4, 2022
Researchers have demonstrated the clinical importance of COVID-19 vaccination after anti-CD19 chimeric antigen receptor (CAR) ...
Leah SherwoodTransplantation & Cellular Therapy | July 29, 2022
The FDA has granted Fast Track Designation and Rare Pediatric Disease Designation for WU-CART-007.
Cecilia BrownAggressive B-Cell Lymphoma | July 25, 2022
Axicabtagene ciloleucel, an autologous anti-CD19 CAR T-cell treatment, improved quality of life compared to standard of care ...
Leah SherwoodTransplantation & Cellular Therapy | July 19, 2022
Axicabtagene ciloleucel is the most cost-effective chimeric antigen receptor (CAR) T-cell therapy for patients with relapsed ...
Leah SherwoodAggressive B-Cell Lymphoma | July 15, 2022
The European Medicines Agency validated a type II variation for the extension of the indication for lisocabtagene maraleucel ...
Editorial Board